Johnson Pharmacare Intrinsic Value
Johnson Pharmacare (JOHNPHARMA) median intrinsic value is ₹1.35 from 1 valuation models (range ₹1–₹1), vs current price ₹0.54 — +150.0% upside (Trading Below Calculated Value), margin of safety 60.0%. Also explore JOHNPHARMA share price history to track price trends across different timeframes.
JOHNPHARMA Valuation Methods Summary — DCF, Graham Number & P/E
Johnson Pharmacare intrinsic value across 1 models vs current price ₹0.54 — upside/downside and value range per method. Browse JOHNPHARMA financial statements for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹1.35 | ₹1.22 - ₹1.49 | +150.0% | Book Value/Share: ₹10.18, P/B: 1.0x |
JOHNPHARMA Intrinsic Value vs Market Price — All Valuation Models
Johnson Pharmacare fair value range ₹1–₹1 vs current market price ₹0.54 across 1 valuation models. For current market price and key ratios, visit Johnson Pharmacare screener.
JOHNPHARMA Intrinsic Value Analysis — Undervalued or Overvalued?
Johnson Pharmacare median intrinsic value ₹1.35, current price ₹0.54 — Trading Below Calculated Value by 150.0%, margin of safety 60.0%.
What is the intrinsic value of JOHNPHARMA?
Based on our comprehensive analysis using 1 different valuation methods, the estimated intrinsic value of Johnson Pharmacare (JOHNPHARMA) is ₹1.35 (median value). With the current market price of ₹0.54, this represents a +150.0% variance from our estimated fair value.
The valuation range spans from ₹1.35 to ₹1.35, indicating ₹1.35 - ₹1.35.
Is JOHNPHARMA undervalued or overvalued?
Based on our multi-method analysis, Johnson Pharmacare (JOHNPHARMA) appears to be trading below calculated value by approximately 150.0%.
JOHNPHARMA Financial Health — Key Ratios vs Industry Benchmarks
Johnson Pharmacare financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.00 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | -1.8% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
JOHNPHARMA Cash Flow Quality — Operating & Free Cash Flow
Johnson Pharmacare operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-2 Cr | ₹-2 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹5 Cr | ₹3 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |